Literature DB >> 32975686

Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study.

Joshua P Kronenfeld1, Emily L Ryon1, David Goldberg2, Rachel M Lee3, Adam Yopp4, Annie Wang5, Ann Y Lee5, Sommer Luu6, Cary Hsu6, Eric Silberfein6, Maria C Russell3, Alan S Livingstone1, Nipun B Merchant1, Neha Goel7.   

Abstract

BACKGROUND: While hepatocellular carcinoma (HCC) is ideally diagnosed outpatient by screening at-risk patients, many are diagnosed in Emergency Departments (ED) due to undiagnosed liver disease and/or limited access-to-healthcare. This study aims to identify sociodemographic/clinical factors associated with being diagnosed with HCC in the ED to identify patients who may benefit from improved access-to-care.
METHODS: HCC patients diagnosed between 2012 and 2014 in the ED or an outpatient setting [Primary Care Physician (PCP) or hepatologist] were identified from the US Safety-Net Collaborative database and underwent retrospective chart-review. Multivariable regression identified predictors for an ED diagnosis.
RESULTS: Among 1620 patients, median age was 60, 68% were diagnosed outpatient, and 32% were diagnosed in the ED. ED patients were more likely male, Black/Hispanic, uninsured, and presented with more decompensated liver disease, aggressive features, and advanced clinical stage. On multivariable regression, controlling for age, gender, race/ethnicity, poverty, insurance, and PCP/navigator access, predictors for ED diagnosis were male (odds ratio [OR] 1.6, 95% confidence interval [CI]: 1.1-2.2, p = 0.010), black (OR 1.7, 95% CI: 1.2-2.3, p = 0.002), Hispanic (OR 1.6, 95% CI: 1.1-2.6, p = 0.029), > 25% below poverty line (OR 1.4, 95% CI: 1.1-1.9, p = 0.019), uninsured (OR 3.9, 95% CI: 2.4-6.1, p < 0.001), and lack of PCP (OR 2.3, 95% CI: 1.5-3.6, p < 0.001) or navigator (OR 1.8, 95% CI: 1.3-2.5, p = 0.001).
CONCLUSIONS: The sociodemographic/clinical profile of patients diagnosed with HCC in EDs differs significantly from those diagnosed outpatient. ED patients were more likely racial/ethnic minorities, uninsured, and had limited access to healthcare. This study highlights the importance of improved access-to-care in already vulnerable populations.

Entities:  

Mesh:

Year:  2020        PMID: 32975686      PMCID: PMC8099037          DOI: 10.1245/s10434-020-09156-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  23 in total

1.  High Rate of Hospital Admissions Among Patients with Cirrhosis Seeking Care in US Emergency Departments.

Authors:  Chanda K Ho; Judith H Maselli; Norah A Terrault; Ralph Gonzales
Journal:  Dig Dis Sci       Date:  2015-02-28       Impact factor: 3.199

2.  Hepatocellular carcinoma surveillance rates in commercially insured patients with noncirrhotic chronic hepatitis B.

Authors:  D S Goldberg; A Valderrama; R Kamalakar; S S Sansgiry; S Babajanyan; J D Lewis
Journal:  J Viral Hepat       Date:  2015-01-12       Impact factor: 3.728

3.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

4.  Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance.

Authors:  David S Goldberg; Adriana Valderrama; Rajesh Kamalakar; Sujit S Sansgiry; Svetlana Babajanyan; James D Lewis
Journal:  J Clin Gastroenterol       Date:  2016-03       Impact factor: 3.062

5.  Diagnostic delays are common among patients with hepatocellular carcinoma.

Authors:  Nishant Patel; Adam C Yopp; Amit G Singal
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

6.  The Gastroenterologist's Guide to Preventive Management of Compensated Cirrhosis.

Authors:  Akshay Shetty; Jung Jun Yum; Sammy Saab
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-08

7.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

8.  Urban-Rural Disparity in Cancer Incidence, Mortality, and Survivals in Shanghai, China, During 2002 and 2015.

Authors:  Xiaopan Li; Yang Deng; Weina Tang; Qiao Sun; Yichen Chen; Chen Yang; Bei Yan; Yingying Wang; Jing Wang; Shuo Wang; Fan Yang; Yibo Ding; Genming Zhao; Guangwen Cao
Journal:  Front Oncol       Date:  2018-12-03       Impact factor: 6.244

Review 9.  Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?

Authors:  Hadar Meringer; Oren Shibolet; Liat Deutsch
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

10.  Continuing Challenges in Rural Health in the United States.

Authors:  Steven S Coughlin; Catherine Clary; J Aaron Johnson; Adam Berman; Vahe Heboyan; Teal Benevides; Justin Moore; Varghese George
Journal:  J Environ Health Sci       Date:  2019-12-16       Impact factor: 3.433

View more
  1 in total

1.  Surgical oncology operative experience at a high-volume safety-net hospital during the COVID-19 pandemic.

Authors:  Joshua P Kronenfeld; Amber L Collier; Seraphina Choi; Dayana Perez-Sanchez; Ankit M Shah; Christina Lee; Neha Goel
Journal:  J Surg Oncol       Date:  2021-07-22       Impact factor: 2.885

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.